Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

@article{Cohen2012AlemtuzumabVI,
  title={Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial},
  author={Jeffrey A. Cohen and Alasdair J. Coles and Douglas L. Arnold and Christian Confavreux and Edward J. Fox and H. P. Hartung and Eva Kubala Havrdov{\'a} and Krzysztof W Selmaj and Howard L. Weiner and Elizabeth Fisher and Vesna V. Brinar and Gavin Giovannoni and Miroslav Stojanovi{\'c} and Bella Ertik and Stephen L. Lake and David H. Margolin and Michael A. Panzara and D Alastair S Compston},
  journal={The Lancet},
  year={2012},
  volume={380},
  pages={1819-1828}
}
View on Elsevier
colescambridge.org.uk
981 Citations
Highly Influential Citations
57
Background Citations
210
Methods Citations
63
Results Citations
41

Figures and Tables from this paper

981 Citations

Citation Type

Citation Type

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)
TLDR
Alemtuzumab was efficacious in a small cohort of relapsing-remitting MS patients of African descent over 8 years, and safety was consistent with the overall CARE-MS population, although the small sample size may have prevented the detection of known low-frequency adverse events.
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
TLDR
Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL in phase 3 trials in patients with relapsing-remitting multiple sclerosis.
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
TLDR
Trial results support alemtuzumab’s manageable, consistent safety profile in relapsing–remitting multiple sclerosis and recommend education, vigilance by physicians and patients, and monthly laboratory monitoring are recommended to maintain alemTuzumabs positive benefit:risk profile.
Induction of disease remission with one cycle of alemtuzumab in relapsing–remitting MS
TLDR
The data suggests that induction of disease remission for some patients might occur following just one dose of alemtuzumab, which could support modification of the current therapy regimen.
Alemtuzumab as rescue therapy in a cohort of 16 aggressive multiple sclerosis patients previously treated by Mitoxantrone: an observational study
TLDR
Safety and neurological impact of alemtuzumab as last-line rescue therapy in aggressive multiple sclerosis patients, previously treated by Mitoxantrone, control aggressive RRMS despite previous use of MITOX is described.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
TLDR
This study demonstrates the high efficacy of alemtuzumab over 6 years, with a similar safety profile between treatment groups; however, disability outcomes were less favorable versus alemTuzUMab-only patients.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study
TLDR
Therapy switch was highly effective in reducing clinical and MRI surrogates of disease activity and was mainly well tolerated within one year of follow-up, indicating alemtuzumab constitutes a promising therapy in RRMS with refractory disease activity despite fingolimod treatment.
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
TLDR
To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of people with RRMS to prevent disease activity, the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register was searched.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
TLDR
In patients with early, relapsing-remitting multiple sclerosis, alemtuzumab was more effective than interferon beta-1a but was associated with autoimmunity, most seriously manifesting as immune thrombocytopenic purpura.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
TLDR
Class III evidence is provided that alemtuzumab is more effective than interferon β-1a in reducing relapses and disability in patients with RRMS in a long-term follow-up of a rater-blinded, randomized clinical trial with 59.5% of patients participating in the extended follow- up period.
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Randomized, comparative study of interferon β-1a treatment regimens in MS
TLDR
IFNβ-1a 44 μg subcutaneously tiw was more effective than IFNβ -1a 30 μg IM qw on all primary and secondary outcomes investigated after 24 and 48 weeks of treatment.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
TLDR
Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
TLDR
This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a.
A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
TLDR
There was no difference between IFNβ-1a 30 μg and 60 μg IM in clinical or MRI measures in relapsing MS, and both doses were well tolerated.
...
...